

# Clinical trials of aromatase inhibitors for advanced breast cancer (metastatic) in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 AI alone

Trial	Treatments	Patients	Trials design and methods
<b>letrozole vs aminoglutethimide</b>			
Gershanovich , 1998 n=NA follow-up:	-	postmenopausal women with advanced breast cancer, previously treated with anti-estrogens	
<b>formestane vs anastrozole</b>			
Kleeberg , 1997 n=NA follow-up:	-	women with advanced breast cancer	
<b>letrozole vs anastrozole</b>			
Rose , 2003 n=NA follow-up:	-	second-line endocrine therapy in advanced breast cancer	
<b>letrozole vs atamestane + toremifene</b>			
Goss , 2007 n=NA follow-up:	-	postmenopausal women with advanced receptor-positive breast cancer	
<b>letrozole vs fadrozole</b>			
Tominaga , 2003 n=NA follow-up:	-	-	
<b>anastrozole vs fulvestrant</b>			
Mauriac , 2003 n=NA follow-up:	-	-	
<b>exemestane vs fulvestrant</b>			
Chia , 2008 n=NA follow-up:	-	-	
<b>aminoglutethimide vs hydrocortisone</b>			
Mercer , 1993 n=NA follow-up:	-	second-line hormone treatment of advanced breast cancer	
<b>aminoglutethimide vs medroxyprogesterone acetate</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Canney , 1988 n=NA follow-up:	aminoglutethimide versus high-dose medroxyprogesterone acetate (MPA)	postmenopausal patients with advanced breast carcinoma	
Garcia-Giralt , 1992 n=NA follow-up:	-	and third line hormonotherapy in advanced post-menopausal breast cancerpatients who have become resistant to tamoxifen	
Samonis , 1994 n=NA follow-up:	-	women with metastatic breast cancer	
<b>aminoglutethimide vs megestrol acetate</b>			
Lundgren , 1989 n=NA follow-up:	-	second-line treatment in patients with metastatic breast cancer	
Russell , 1997 n=NA follow-up:	-	second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer:	
<b>anastrozole vs megestrol acetate</b>			
Buzdar a , 1996 n=NA follow-up:	-	postmenopausal patients with advanced breast cancer	
<b>exemestane vs megestrol acetate</b>			
Kaufmann , 2000 n=NA follow-up:	-	postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen	
<b>fadrozole vs megestrol acetate</b>			
Bezwoda , 1998 n=NA follow-up:	-	-	
Buzdar b , 1996 n=NA follow-up:	-	postmenopausal patients with metastatic breast carcinoma:	
Buzdar c , 1996 n=NA follow-up:	-	postmenopausal patients with metastatic breast carcinoma	
<b>formestane vs megestrol acetate</b>			
Freue , 2000 n=NA follow-up:	-	postmenopausal patients with advanced breast cancer previously treated with tamoxifen	
Thuerlimann , 1997 n=NA follow-up:	-	-	
<b>letrozole vs megestrol acetate</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
Buzdar , 2001 n=NA follow-up:	-	postmenopausal women with advanced breast cancer previously treated with antiestrogens	
Dombrowsky , 1998 n=NA follow-up:	-	patients with locally advanced, locoregionally recurrent or metastatic breast cancer	
<b>vorozole vs megestrol acetate</b>			
Goss , 1999 n=NA follow-up:	-	-	
<b>aminoglutethimide vs tamoxifen</b>			
Alonso-Munoz , 1988 n=NA follow-up:	-	advanced postmenopausal breast cancer	
Gale , 1994 n=NA follow-up:	-	postmenopausal women with advanced breast cancer	
<b>anastrozole vs tamoxifen</b>			
TARGET (Bonneterre) , 2001 n=340/328 follow-up:	anastrozole 1 mg once daily versus tamoxifen 20 mg once daily	first-line therapy for advanced breast cancer in 353 postmenopausal women	Parallel groups
Milla-Santos , 2003 n=NA follow-up:	-	first-line therapy in postmenopausal, hormone-dependent, advanced breast cancer	
<b>exemestane vs tamoxifen</b>			
Paridaens , 2003 n=NA follow-up:	exemestane versus tamoxifen	first-line hormone therapy for postmenopausal women with metastatic breast cancer	
<b>fadrozole vs tamoxifen</b>			
Falkson , 1996 n=NA follow-up:	-	previously untreated postmenopausal patients with metastatic breast cancer	
Thuerlimann , 1996 n=NA follow-up:	-	postmenopausal women with advanced breast cancer	
<b>formestane vs tamoxifen</b>			
Perez Carrion , 1994 n=NA follow-up:	-	-	
<b>letrozole vs tamoxifen</b>			
Mourisden , 2001 n=NA follow-up:	-	first-line therapy for postmenopausal women with advanced breast cancer	

## References

### Gershanovich, 1998:

Gershanovich M [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]. *Vopr Onkol.* 1999;45(4):361-8 [[10532092](#)]

Gershanovich, M Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). *Ann. Oncol.* 1998;9:639-45 [[9681078](#)] NA

### Kleeberg, 1997:

Kleeberg UR A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer. *Oncology.* 1997;54 Suppl 2:19-22 [[9394856](#)]

Vorobiof DA A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer. *Ann Oncol.* 1999 Oct;10(10):1219-25 [[10586340](#)]

Fruehauf, JP Docetaxel and vinorelbine plus GM-CSF in malignant melanoma. *Oncology (Williston Park, N.Y.)* 2005;19:19-22 [[15934496](#)] NA

### Rose, 2003:

Rose C An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. *Eur J Cancer.* 2003 Nov;39(16):2318-27 [[14556923](#)]

Tobias JS An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole. *Eur J Cancer.* 2004 Aug;40(12):1913 [[15288295](#)] [10.1016/j.ejca.2004.02.030](#)

### Goss, 2007:

Goss P Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. *J Clin Oncol.* 2007 Nov 1;25(31):4961-6 [[17971594](#)] [10.1200/JCO.2006.09.5455](#)

### Tominaga, 2003:

Tominaga T Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. *Ann Oncol.* 2003 Jan;14(1):62-70 [[12488294](#)]

### Mauriac, 2003:

Howell A Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. *J Clin Oncol.* 2002 Aug 15;20(16):3396-403 [[12177099](#)]

Mauriac L Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. *Eur J Cancer.* 2003 Jun;39(9):1228-33 [[12763210](#)]

Osborne CK Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. *J Clin Oncol.* 2002 Aug 15;20(16):3386-95 [[12177098](#)]

Robertson JFR, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. *Cancer* 2003;98(2):22938.

### Chia, 2008:

Chia S Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFACT. *J Clin Oncol.* 2008 Apr 1;26(10):1664-70 [[18316794](#)] [10.1200/JCO.2007.13.5822](#)

### Mercer, 1993:

Mercer PM, Ebbs SR, Fraser SC, Coltart RS, Bates T Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. *Eur J Surg Oncol* 1993 Jun;19:254-8 [[8314383](#)]

Gui, GP Integrin expression in breast cancer cytology: a novel predictor of axillary metastasis. *Eur J Surg Oncol* 1996;22:254-8 [[8654607](#)] NA

### Canney, 1988:

Canney PA Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. *J Natl Cancer Inst.* 1988 Sep 21;80(14):1147-51 [[2970555](#)]

**Garcia-Giralt, 1992:**

Rijksen G An enzyme-linked immunosorbent assay for the determination of src-family tyrosine kinase activity in breast cancer. *Breast Cancer Res Treat.* 1996;39(2):139-45 [[8872322](#)]

Garcia-Giralt E, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, Guerin D, Guerin R Second and third line hormonotherapy in advanced postmenopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. *Breast Cancer Res Treat* 1992;24:139-45 [[8443401](#)]

**Samonis, 1994:**

Samonis G, Margioris AN, Bafaloukos D, Razis DV Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG+MPA in generalized breast cancer. *Oncology* 1994 Sep-Oct;51:411-5 [[8052481](#)]

Giannotti, D Spider surgical system versus multiport laparoscopic surgery: performance comparison on a surgical simulator. *BMC Surg* 2015;15:54 [[25935155](#)] [10.1186/s12893-015-0038-9](#)

**Lundgren, 1989:**

Lundgren S Megestrol acetate versus aminoglutethimide for metastatic breast cancer. *Breast Cancer Res Treat.* 1989 Nov;14(2):201-6 [[2690972](#)]

**Russell, 1997:**

Russell CA Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. *J Clin Oncol.* 1997 Jul;15(7):2494-501 [[9215817](#)]

**Buzdar a, 1996:**

Buzdar A Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. *J Clin Oncol.* 1996 Jul;14(7):2000-11 [[8683230](#)]

Thomson CA Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets. *Nutr Cancer.* 2010;62(8):1142-52 [[21058203](#)] [10.1080/01635581.2010.513803](#)

Buzdar AU ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer. *J Steroid Biochem Mol Biol.* 1997 Apr;61(3-6):145-9 [[9365184](#)]

Jonat W A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. *Eur J Cancer.* 1996 Mar;32A(3):404-12 [[8814682](#)]

Fabry HF Cosmetic outcome of breast conserving therapy after sentinel node biopsy versus axillary lymph node dissection. *Breast Cancer Res Treat.* 2005 Jul;92(2):157-62 [[15986125](#)] [10.1007/s10549-005-0321-z](#)

Laban, S Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. *Int. J. Cancer* 2014;135:1142-52 [[24482145](#)] [10.1002/ijc.28752](#)

Heikkil, K C-reactive protein-associated genetic variants and cancer risk: findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. *Eur. J. Cancer* 2011;47:404-12 [[20727736](#)] [10.1016/j.ejca.2010.07.032](#)

Drummond M, Thompton E, Howell A, Jonat W, Buzdar A, Brown J. Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer. *Journal of Medical Economics* 1999;2:3343.

Drummond M, Thompton E, Howell A, Jonat W, Buzdar A, Brown J. Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer. *Journal of Medical Economics* 1999;2:3343.

**Kaufmann, 2000:**

Reece-Smith AM A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era. *Eur J Surg Oncol.* 2012 Jun;38(6):484-9 [[22342866](#)] [10.1016/j.ejso.2012.01.011](#)

Kaufmann M Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. *J Clin Oncol.* 2000 Apr;18(7):1399-411 [[10735887](#)]

Schiffmann, J Oncological outcome after radical prostatectomy: Marital status does not make a difference. *Int. J. Urol.* 2015;22:484-9 [[25781055](#)] [10.1111/iju.12717](#)

Kaufmann, M Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. *Clin. Breast Cancer* 2000;1 Suppl 1:S15-8 [[11970744](#)] **NA**

**Bezwoda, 1998:**

Bezwoda WR, Gudgeon A, Falkson G, Jordaan JP, Goedhals L Fadzole versus megestrol acetate: a double-blind randomised trial in advanced breast cancer. *Oncology* 1998;55:416-20 [9732218]

Kobayashi, H [Tend to second-line therapy in lung cancer]. *Gan To Kagaku Ryoho* 2015;42:416-20 [25963689] NA

**Buzdar b, 1996:**

Buzdar AU Fadzole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. *Cancer*. 1996 Jun 15;77(12):2503-13 [8640699] 10.1002/(SICI)1097-0142(19960615)77:12;2503::

**Buzdar c, 1996:**

Buzdar AU Fadzole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. *Cancer*. 1996 Jun 15;77(12):2503-13 [8640699] 10.1002/(SICI)1097-0142(19960615)77:12;2503::

**Freue, 2000:**

Freue M Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen. *Breast*. 2000 Feb;9(1):9-16 [14731578]

**Thuerlimann, 1997:**

Bernhard J Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). *Eur J Cancer*. 1999 Jun;35(6):913-20 [10533471]

Bernhard J Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? *J Clin Oncol*. 1999 Jun;17(6):1672-9 [10561203]

Thrlimann B Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK) *Eur J Cancer*. 1997 Jun;33(7):1017-24 [9376181]

**Buzdar, 2001:**

Buzdar A Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. *J Clin Oncol*. 2001 Jul 15;19(14):3357-66 [11454883]

**Dombernowsky, 1998:**

Dombernowsky P Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. *J Clin Oncol*. 1998 Feb;16(2):453-61 [9469328]

**Goss, 1999:**

Goss PE, Winer EP, Tannock IF, Schwartz LH Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. *J Clin Oncol* 1999 Jan;17:52-63 [10458218]

Martinelli, G IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. *J. Clin. Oncol*. 2009;27:5202-7 [19770381] 10.1200/JCO.2008.21.6408

**Alonso-Munoz, 1988:**

Alonso-Munoz MC, Ojeda-Gonzalez MB, Beltran-Fabregat M, Dorca-Ribugent J, Lopez-Lopez L, Borras-Balada J, Cardenal-Aleman F, Gomez-Batiste X, Fabregat-Mayol J, Viladiu-Quemada P Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. *Oncology* 1988;45:350-3 [3045726]

Scribner, DR Single-site laparoscopic management of a large adnexal mass. *JSLs NA*;17:350-3 [23925036] 10.4293/108680812X13517013318193

**Gale, 1994:**

Gale KE, Andersen JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ, Cummings FJ Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. *Cancer* 1994 Jan 15;73:354-61 [8293400]

Kim, SY What to do with thyroid nodules showing benign cytology and BRAF(V600E) mutation? A study based on clinical and radiologic features using a highly sensitive analytic method. *Surgery* 2015;157:354-61 [25616949] 10.1016/j.surg.2014.09.003

**TARGET (Bonnetterre), 2001:**

Escalín MP Pharmacotherapy of large B-cell lymphoma. *Expert Opin Pharmacother.* 2008 Sep;9(13):2247-58 [[18710350](#)] [10.1517/14656566.9.13.2247](#)

Cabeza M Antiandrogenic and apoptotic effects of RU-486 on animal prostate. *J Steroid Biochem Mol Biol.* 2007 May;104(3-5):321-5 [[17466516](#)] [10.1016/j.jsbmb.2007.03.009](#)

Nabholtz JM Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. *Eur J Cancer.* 2003 Aug;39(12):1684-9 [[12888362](#)]

Nabholtz JM Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. *J Clin Oncol.* 2000 Nov 15;18(22):3758-67 [[11078488](#)]

Bonnetterre, J Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. *J. Clin. Oncol.* 2000;18:3748-57 [[11078487](#)] NA

Thuerlimann B, Robertson JFR, Nabholz JM, Buzdar A, Bonnetterre J. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. *European Journal of Cancer* 2003;39:231017.

Thuerlimann B, Robertson JFR, Nabholz JM, Buzdar A, Bonnetterre J. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. *European Journal of Cancer* 2003;39:231017.

#### **Milla-Santos, 2003:**

Milla-Santos A Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. *Am J Clin Oncol.* 2003 Jun;26(3):317-22 [[12796608](#)] [10.1097/01.COC.0000047126.10522.F9](#)

#### **Paridaens, 2003:**

Atalay G The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. *Ann Oncol.* 2004 Feb;15(2):211-7 [[14760111](#)]

Paridaens R Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. *Ann Oncol.* 2003 Sep;14(9):1391-8 [[12954578](#)]

#### **Falkson, 1996:**

Falkson CI A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. *Ann Oncol.* 1996 Jul;7(5):465-9 [[8839900](#)]

#### **Thuerlimann, 1996:**

Thrlimann B First-line fadrozole HCl (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. *Ann Oncol.* 1996 Jul;7(5):471-9 [[8839901](#)]

#### **Perez Carrion, 1994:**

Prez Carrin R Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. *Ann Oncol.* 1994;5 Suppl 7:S19-24 [[7873457](#)]

#### **Mouridsen, 2001:**

Irish W Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. *Ann Oncol.* 2005 Sep;16(9):1458-62 [[15946978](#)] [10.1093/annonc/mdi275](#)

Lipton A Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. *J Clin Oncol.* 2003 May 15;21(10):1967-72 [[12743150](#)] [10.1200/JCO.2003.09.098](#)

Mouridsen H Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. *Oncologist.* 2004;9(5):497-506 [[15477634](#)] [10.1634/theoncologist.9-5-497](#)

Mouridsen H Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. *J Clin Oncol.* 2003 Jun 1;21(11):2101-9 [[12775735](#)] [10.1200/JCO.2003.04.194](#)

Mouridsen H Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. *J Clin Oncol.* 2001 May 15;19(10):2596-606 [[11352951](#)]

Mouridsen HT Letrozole in advanced breast cancer: the PO25 trial. *Breast Cancer Res Treat.* 2007;105 Suppl 1:19-29 [[17333340](#)] [10.1007/s10549-007-9527-6](#)

Lim, JC Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast. *Breast Cancer Res. Treat.* 2015;150:19-29 [25677742] [10.1007/s10549-015-3296-4](https://doi.org/10.1007/s10549-015-3296-4)

## 2 combination including AI

Trial	Treatments	Patients	Trials design and methods
<b>aminoglutethimide + tamoxifen vs tamoxifen</b>			
Ingle , 1986 n=NA follow-up:	tamoxifen alone versus TAM plus aminoglutethimide (AG) and hydrocortisone (HC).	-	
Rose , 1986 n=NA follow-up:	-	postmenopausal patients with advanced breast cancer	
<b>combination of hormone therapies vs tamoxifen</b>			
Powles , 1984 n=NA follow-up:	combination of hormone therapies using tamoxifen, aminoglutethimide with hydrocortisone, and danazol (TAD) versus tamoxifen	-	

∞

## References

### Ingle, 1986:

Ingle JN Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. *J Clin Oncol.* 1986 Jun;4(6):958-64 [3519885]

### Rose, 1986:

Cassano E Ultrasound-guided vacuum-assisted core breast biopsy: experience with 406 cases. *Breast Cancer Res Treat.* 2007 Mar;102(1):103-10 [16838109] [10.1007/s10549-006-9305-x](https://doi.org/10.1007/s10549-006-9305-x)  
 Rose C Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. *Breast Cancer Res Treat.* 1986;7 Suppl:S45-50 [3527306]

### Powles, 1984:

Powles TJ Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. *Lancet.* 1984 Jun 23;1(8391):1369-73 [6145832]

## 3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.